Monthly Archives

June 2019

Highlights from European Stroke Organisation Conference (ESOC) Scientific Symposium

By News

June 2019

A scientific symposium was held on the 24th May 2019, which aimed to share the advance of stroke rehabilitation and the role of NeuroAiD in post-stroke recovery.

Clinicians from Southeast Asia, Europe, and Middle-East attended the symposium. International faculties presented their perspectives on patients’ journey through stroke recovery and the critical role of both rehabilitation and NeuroAiD to achieve functional independence.

  • Professor Christopher Chen from the National University of Singapore provided an overall perspective and moderated the entire scientific session
  • Professor Pamela Duncan from Wake Forest University of the United States of America, presented stroke recovery therapeutics and rehabilitation
  • Professor NV Ramani from Raffles Hospital Singapore, presented the effects of NeuroAiD on long-term functional outcomes after stroke
  • Professor Suwanwela NC from Chulalongkorn University Thailand, presented the effects of combination treatment with NeuroAiD and rehabilitation
  • Professor M Lazdunski from CNRS France, presented NeuroAiD’s multimodal mode of action

Professor Duncan emphasized that “we are transforming acute care”. Indeed, the mortality rate of stroke patients in the United States is decreasing, however, “we are not managing the disability” among these patients. In other words, “stroke patients are living longer, with higher chance of survival, but they are not given with optimal recovery”. It is important to note that in “rehab and recovery, there is reorganization of the brain, neurogenesis, regulation of growth factors, and all of these processes take time. Therefore the “primary endpoint of clinical trials assessing recovery should be 6 months to 1 year”, she added.

 

CHIMES-E Study

CHIMES-E, NeuroAiD’s landmark study, assessed recovery for up to 2 years following a stroke. More patients in the treatment group achieved functional independence (mRS 0-1) with significant results from month 6 to 18 compared to the placebo group. Moreover, combining NeuroAiD and rehabilitation doubled the odds of achieving functional independence as early as month-3, with effect persisting over 2 years as compared to patients who underwent rehabilitation alone.

 

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.

 

Moleac holds two educational symposia on the management of Traumatic Brain Injury

By News

March 2019

Moleac organized two symposia in Dubai and Bangkok on new approaches for Traumatic Brain Injury (TBI) recovery.

In these symposia, the speakers emphasized on the global burden of TBI, the lack of treatment options for patients, and the scientific and clinical background supporting the role of NeuroAiD to help patients who have suffered from a TBI and other brain injuries.

Clinicians from Southeast Asia, Europe, and Middle-East attended the sessions presented by International faculties:

Professor Valery Feigin (MD, MSc, PhD, FAAN), director from the AUT National Institute for Stroke and Applied Neuroscience from New Zealand, presented the BRAINS Study assessing the safety and efficacy of NeuroAiD in TBI patients.

  • Professor Mihai Berteanu (MD, PhD), senior consultant from Elias University Hospital, Romania, discussed about the consistency of NeuroAiD’s neurorestorative properties across brain injuries.
  • Associate Professor Ihsan K. Al-Shimmery from Hawler Medical University in Iraq, presented the effect of combining rehabilitation with NeuroAiD.
  • Lee Khean Hin from Gleneagles Hospital Singapore, shared his clinical experience of using NeuroAiD in several types of brain injuries.
  • Associate Professor Ramesh Kumar (MD, MRCS, FRCS) from the National University of Malaysia (UKM), one of the primary investigators for SATURN and NeST registry in Malaysia, presented the preliminary findings for these two studies.

 

The BRAINS Study

The BRAINS Study was conducted in New Zealand and published in the European Journal of Neurology in April 2018. It investigated the clinical relevance of NeuroAiD for mild-to-moderate TBI patients who suffered from persistent cognitive deficits. Complex Attention (ability to multi-task) and Executive Functioning (planning and decision making) are the most commonly affected cognitive domains following a TBI. Both cognitive domains were significantly improved after a 6-month treatment of NeuroAiD versus placebo and over the 9-month follow-up period, with a good safety profile.

In addition to the BRAINS study, ongoing research on the potential role of NeuroAiD in Spinal Cord Injury (SCI) and case reports of Intra Cranial Hemorrhage (ICH) and TBI confirm the safety profile of NeuroAiD and its promising role in improving recovery after brain injuries.

 

NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.

Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.